Effects of everolimus: A Synthesis of Findings from 14 Studies
- Home
- Effects of everolimus
This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of everolimus: A Synthesis of Findings from 14 Studies", please consult your doctor.
For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
Major research findings
Everolimus is an mTOR (mammalian target of rapamycin) inhibitor, which has shown promising results in treating various cancers. Everolimus's anticancer effects are achieved through different mechanisms, including suppressing tumor cell growth, inducing apoptosis, and inhibiting angiogenesis. Several studies have shown that everolimus can be effective both as a monotherapy and in combination with other anticancer drugs. For example, a study in 6 demonstrated that everolimus inhibits the growth of gastric cancer cells and induces apoptosis. Another study in 8 showed that everolimus suppresses the growth of ovarian clear cell cancer stem-like cells and induces apoptosis. Furthermore, a study in 14 demonstrated that everolimus inhibits the growth of adriamycin-resistant breast cancer cells. These studies suggest that everolimus could be a potential anticancer drug for various cancers.
Benefits and risks
Benefit summary
Everolimus has been shown to be effective in treating various cancers in numerous studies. Notably, its mTOR inhibition action holds promise for suppressing tumor cell growth, inducing apoptosis, and inhibiting angiogenesis. In a study published in 6 , everolimus demonstrated its ability to suppress the growth of gastric cancer cells and induce apoptosis. Additionally, a study in 8 revealed that everolimus inhibits the growth of ovarian clear cell cancer stem-like cells and induces apoptosis. Furthermore, research in 14 showed that everolimus effectively inhibits the growth of adriamycin-resistant breast cancer cells.
Risk summary
Everolimus has been reported to cause several side effects. The most common side effects include stomatitis, leukopenia, anorexia, anemia, and fatigue. A study published in 3 reported these side effects as a result of everolimus treatment. These side effects are usually mild to moderate and don't require treatment discontinuation. However, severe side effects can occur, and treatment might need to be stopped in such cases. As an immunosuppressant, everolimus could increase the risk of infections. Therefore, caution is advised regarding infections while taking everolimus. Additionally, everolimus should not be used by pregnant women. Lactating women should also stop breastfeeding while taking everolimus.
Comparison between studies
Similarities between studies
Several studies have shown that everolimus inhibits tumor cell growth and induces apoptosis. This is believed to be due to everolimus inhibiting mTOR, thereby suppressing cell growth and proliferation. Moreover, the side effects of everolimus have been found to be relatively mild. Many patients experience mild to moderate side effects such as stomatitis, leukopenia, anorexia, anemia, and fatigue.
Differences between studies
The efficacy of everolimus varies depending on the type of cancer and the accompanying treatment regimen. For instance, a study in 6 showed that everolimus was effective against gastric cancer cells, but it might not be effective against other cancer types. Additionally, while a study in 14 showed that everolimus was effective against adriamycin-resistant breast cancer cells, the effects may differ when combined with other anticancer drugs.
Consistency and contradictions in the results
The efficacy of everolimus is influenced by various factors, including the type of cancer, the accompanying treatment regimen, and the patient's overall condition. Therefore, the same effect cannot be guaranteed for all patients. Additionally, the side effects of everolimus vary from patient to patient. Various side effects, ranging from mild to severe, could occur. Therefore, it is crucial to consult a physician before taking everolimus and select an appropriate treatment regimen.
Cautions for real-life application
While everolimus is a potentially effective drug for treating cancer, it carries the risk of side effects. Therefore, it is crucial to consult a physician before taking everolimus and choose the appropriate treatment regimen. As an immunosuppressant, everolimus could increase the risk of infections. Therefore, caution is advised regarding infections while taking everolimus. Additionally, everolimus should not be used by pregnant women. Lactating women should also stop breastfeeding while taking everolimus.
Limitations of current research
Current research has demonstrated that the efficacy of everolimus varies depending on the type of cancer and the accompanying treatment regimen. However, further studies are needed to investigate the effects of everolimus in greater detail. Notably, it is important to examine the potential influence of the patient's genotype and cancer cell genetic mutations on the efficacy of everolimus.
Future research directions
Future research should focus on investigating the effects of everolimus in greater detail. Specifically, it is crucial to examine the potential influence of the type of cancer and the accompanying treatment regimen on the efficacy of everolimus. Additionally, further research is needed to understand the side effects of everolimus in more depth. Notably, it is crucial to assess the risk of developing severe side effects and explore ways to mitigate them.
Conclusion
Everolimus holds promise as a treatment for various cancers. Multiple studies have shown that everolimus inhibits tumor cell growth and induces apoptosis. However, everolimus carries the risk of side effects. Therefore, it is crucial to consult a physician before taking everolimus and choose the appropriate treatment regimen. Research on everolimus is still in its early stages, and further investigation is needed. Future research could shed more light on the efficacy of everolimus, ultimately benefiting more patients.
Benefit Keywords
Risk Keywords
Article Type
Author: CiunciChristine A, PeriniRodolfo F, AvadhaniAnjali N, KangHyunseon C, SunWeijing, RedlingerMaryann, HarlackerKathleen, FlahertyKeith T, GiantonioBruce J, RosenMark A, DivgiChaitanya R, SongHee Kwon, EnglanderSarah, TroxelAndrea, SchnallMitchell, O'DwyerPeter J
Language : English
Author: FazioNicola, CarnaghiCarlo, BuzzoniRoberto, ValleJuan W, HerbstFabian, RidolfiAntonia, StrosbergJonathan, KulkeMatthew H, PavelMarianne E, YaoJames C
Language : English
Author: ArenaClaudia, BizzocaMaria Eleonora, CaponioVito Carlo Alberto, TroianoGiuseppe, ZhurakivskaKhrystyna, LeuciStefania, Lo MuzioLorenzo
Language : English
Author: ShirzadShima, VafaeeFarzaneh, ForouzanfarFatemeh
Language : English
Author: ZhangZixin, QiuTong, ZhouJiangyuan, GongXue, YangKaiying, ZhangXuepeng, LanYuru, YangCongxia, ZhouZilong, JiYi
Language : English
Author: CaoBo, ZhaoRuiyang, LiHanghang, XuXingming, GaoJingwang, ChenLin, WeiBo
Language : English
Author: RostamzadehDavoud, HaghshenasMohammad Reza, SamadiMahdi, MojtahediZahra, BabalooZohreh, GhaderiAbbas
Language : English
Author: HoChih-Ming, LeeFa-Kung, YenTing-Lin, HuangShih-Hung, ChengWen-Fang
Language : English
Author: GaoFeng, LiRui, WeiPei-Feng, OuLi, LiMin, BaiYang, LuoWen-Jia, FanZheng
Language : English
Author: BernardSarah, PoonAndrew C, TamPeyton M, MutsaersAnthony J
Language : English
Author: ArenaClaudia, BizzocaMaria Eleonora, CaponioVito Carlo Alberto, TroianoGiuseppe, ZhurakivskaKhrystyna, LeuciStefania, Lo MuzioLorenzo
Language : English
Author: ToKimberly, CaoRuoqiong, YegiazaryanAram, OwensJames, SasaniniaKayvan, VaughnCharles, SinghMohkam, TruongEdward, SathananthanAirani, VenketaramanVishwanath
Language : English
Author: JeongHyehyun, JeongJae Ho, KimJeong Eun, AhnJin-Hee, JungKyung Hae, KohSu-Jin, CheonJaekyung, SohnJoohyuk, KimGun Min, LeeKeun Seok, SimSung Hoon, ParkIn Hae, KimSung-Bae
Language : English
Author: XuTinghua, LiuPengxi, LiQingming, ShiChangbin, WangXinjie
Language : English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.